ANDA 74317, held by Watson Laboratories. Hydromorphone Hydrochloride.
As of Nov 21, 2026, ANDA 74317 (Hydromorphone Hydrochloride), held by Watson Laboratories, was first approved by FDA on Aug 23, 1995, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydromorphone Hydrochloride10MG/ML · injectable;injection | Hydromorphone Hydrochloride | Discontinued |
| May 11, 1999 | Supplement 6Manufacturing | Approved | None posted |
| Feb 19, 1999 | Supplement 5Manufacturing | Approved | None posted |
| Feb 2, 1999 | Supplement 3Manufacturing | Approved | None posted |
| May 6, 1997 | Supplement 2Manufacturing | Approved | None posted |
| Dec 4, 1996 | Supplement 1Manufacturing | Approved | None posted |
| Aug 23, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters